Semaglutide Injection, Solution
NDC Package 0420-9237-02

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is an UNFINISHED DRUG part of the official NDC directory. Unfinished drugs include products like active ingredients some of which are used in bulk for further processing or compounding. The FDA requires a list of these drugs manufactured in a U.S. commercial distribution facility.

Semaglutide injection is semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. This formulation utilizes a injection, solution delivery system. Marketed by Novo Nordisk A/s, this product is identified by NDC 0420-9237.

Identification & Billing

NDC Package Code
0420-9237-02
Package Description
375 CONTAINER in 1 BOX / 1 CARTRIDGE in 1 CONTAINER / 3 mL in 1 CARTRIDGE
Product Code
0420-9237
11-Digit Billing Format
00420923702

Clinical Specifications

Proprietary Name
Semaglutide
Non-Proprietary Name
Semaglutide
Substance Name
Semaglutide
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Active Ingredient(s)
SEMAGLUTIDE .68 mg/mL
Usage Information
Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

Regulatory & Marketing

Labeler Name
Novo Nordisk A/s
Product Type
Drug For Further Processing
Marketing Category
DRUG FOR FURTHER PROCESSING - A drug (other than the bulk ingredient API) that is in an interim stage of manufacture, processing, preparation, or packaging, and not ready for human or animal use.
Start Marketing Date
12-06-2017
Listing Expiration
12-31-2026
Exclude Flag
N
Unfinished Product
Yes
Sample Package
N/A

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0420-9237-02 identifies a specific commercial package of 375 container in 1 box / 1 cartridge in 1 container / 3 ml in 1 cartridge of Semaglutide (UNFINISHED drug), drug for further processing labeled by Novo Nordisk A/s. This injection, solution is formulated for use and contains semaglutide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Novo Nordisk A/s on December 06, 2017. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

How is this Novo Nordisk A/s product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00420923702. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0420-9237-02
11-Digit CMS (5-4-2)
00420-9237-02

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.